These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30788638)

  • 1. Complexation with C
    Grebinyk A; Prylutska S; Grebinyk S; Prylutskyy Y; Ritter U; Matyshevska O; Dandekar T; Frohme M
    Nanoscale Res Lett; 2019 Feb; 14(1):61. PubMed ID: 30788638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C
    Grebinyk A; Prylutska S; Buchelnikov A; Tverdokhleb N; Grebinyk S; Evstigneev M; Matyshevska O; Cherepanov V; Prylutskyy Y; Yashchuk V; Naumovets A; Ritter U; Dandekar T; Frohme M
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31717305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of Chemo- and Photodynamic Therapies with C
    Grebinyk A; Prylutska S; Chepurna O; Grebinyk S; Prylutskyy Y; Ritter U; Ohulchanskyy TY; Matyshevska O; Dandekar T; Frohme M
    Nanomaterials (Basel); 2019 Oct; 9(11):. PubMed ID: 31671590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C
    Grebinyk A; Grebinyk S; Prylutska S; Ritter U; Matyshevska O; Dandekar T; Frohme M
    Free Radic Biol Med; 2018 Aug; 124():319-327. PubMed ID: 29940354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic Effects of Dimorfolido-N-Trichloroacetylphosphorylamide and Dimorfolido-N-Benzoylphosphorylamide in Combination with C
    Prylutska S; Grynyuk I; Grebinyk A; Hurmach V; Shatrava I; Sliva T; Amirkhanov V; Prylutskyy Y; Matyshevska O; Slobodyanik M; Frohme M; Ritter U
    Nanoscale Res Lett; 2017 Dec; 12(1):124. PubMed ID: 28235359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fullerene C
    Franskevych D; Palyvoda K; Petukhov D; Prylutska S; Grynyuk I; Schuetze C; Drobot L; Matyshevska O; Ritter U
    Nanoscale Res Lett; 2017 Dec; 12(1):40. PubMed ID: 28091953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of C60 Fullerene-Doxorubicin Complex for Tumor Cell Treatment In Vitro and In Vivo.
    Panchuk RR; Prylutska SV; Chumakl VV; Skorokhyd NR; Lehka LV; Evstigneev MP; Prylutskyy YI; Berger W; Heffeter P; Scharff P; Ritter U; Stoika RS
    J Biomed Nanotechnol; 2015 Jul; 11(7):1139-52. PubMed ID: 26307837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C
    Grebinyk A; Prylutska S; Grynyuk I; Kolp B; Hurmach V; Sliva T; Amirkhanov V; Trush V; Matyshevska O; Slobodyanik M; Prylutskyy Y; Frohme M; Ritter U
    Nanoscale Res Lett; 2018 Mar; 13(1):81. PubMed ID: 29524037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of photoexcited C
    Franskevych D; Prylutska S; Grynyuk I; Pasichnyk G; Drobot L; Matyshevska O; Ritter U
    Bioimpacts; 2019; 9(4):211-217. PubMed ID: 31799157
    [No Abstract]   [Full Text] [Related]  

  • 10. A Novel Nanoconjugate of Landomycin A with C
    Bilobrov V; Sokolova V; Prylutska S; Panchuk R; Litsis O; Osetskyi V; Evstigneev M; Prylutskyy Y; Epple M; Ritter U; Rohr J
    Cell Mol Bioeng; 2019 Feb; 12(1):41-51. PubMed ID: 31719898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPLC-ESI-MS method for C
    Grebinyk A; Grebinyk S; Prylutska S; Ritter U; Matyshevska O; Dandekar T; Frohme M
    Data Brief; 2018 Aug; 19():2047-2052. PubMed ID: 30229080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C
    Skivka LM; Prylutska SV; Rudyk MP; Khranovska NM; Opeida IV; Hurmach VV; Prylutskyy YI; Sukhodub LF; Ritter U
    Cancer Nanotechnol; 2018; 9(1):8. PubMed ID: 30416604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of C
    Prylutska S; Grynyuk I; Skaterna T; Horak I; Grebinyk A; Drobot L; Matyshevska O; Senenko A; Prylutskyy Y; Naumovets A; Ritter U; Frohme M
    Arch Toxicol; 2019 May; 93(5):1213-1226. PubMed ID: 30989314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment.
    Prylutska S; Grynyuk I; Matyshevska O; Prylutskyy Y; Evstigneev M; Scharff P; Ritter U
    Drugs R D; 2014 Dec; 14(4):333-40. PubMed ID: 25504158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of C60 fullerene complexation with antibiotic doxorubicin.
    Prylutskyy YI; Evstigneev MP; Pashkova IS; Wyrzykowski D; Woziwodzka A; Gołuński G; Piosik J; Cherepanov VV; Ritter U
    Phys Chem Chem Phys; 2014 Nov; 16(42):23164-72. PubMed ID: 25251969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis photoinduction by C60 fullerene in human leukemic T cells.
    Palyvoda KO; Grynyuk II; Prylutska SV; Samoylenko AA; Drobot LB; Matyshevska OP
    Ukr Biokhim Zh (1999); 2010; 82(4):121-7. PubMed ID: 21513214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy.
    Shi J; Liu Y; Wang L; Gao J; Zhang J; Yu X; Ma R; Liu R; Zhang Z
    Acta Biomater; 2014 Mar; 10(3):1280-91. PubMed ID: 24211343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncovalent interaction assisted fullerene for the transportation of some brain anticancer drugs: A theoretical study.
    Samanta PN; Das KK
    J Mol Graph Model; 2017 Mar; 72():187-200. PubMed ID: 28110183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy.
    Prylutska SV; Skivka LM; Didenko GV; Prylutskyy YI; Evstigneev MP; Potebnya GP; Panchuk RR; Stoika RS; Ritter U; Scharff P
    Nanoscale Res Lett; 2015 Dec; 10(1):499. PubMed ID: 26714861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C
    Hurmach Y; Rudyk M; Prylutska S; Hurmach V; Prylutskyy YI; Ritter U; Scharff P; Skivka L
    Mol Pharm; 2020 Sep; 17(9):3622-3632. PubMed ID: 32673486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.